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SUMMARY Hidradenitis suppurativa (HS) is a chronic, inflammatory disease 
characterized by recurring abscesses, nodules, and fistulas predominantly 
in the area of the groin and axillae. The association between HS and Crohn´s 
disease (CD) has already been documented. We report on a case of a patient 
with CD associated HS, refractory to multiple local and systemic agents.A 
complete resolution of both diseases was finally achieved after treatment 
with adalimumab. Our case report supports the co-occurrence of both dis-
eases and suggests that adalimumab approved for CD might also be a safe 
and effective therapeutic option in the treatment of HS.
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INTRODUCTION
Crohn´s disease (CD) is a sporadic inflammatory 
disorder of unknown etiology that primarily affects 
the gastrointestinal tract and often results in dis-
continuous transmural inflammation. Extraintestinal 
manifestations are observed in 20-40% of affected 
patients. Dermatological complications include pyo-
derma gangrenosum, erythema nodosum, psoriasis, 
necrotizing cutaneous vasculitis, and epidermolysis 
bullosa acquisita (1,2).
Hidradenitis suppurativa (HS) is a chronic inflam-
matory disease of unknown pathogenesis, character-
ized by recurring painful abscesses, nodules, and fis-
tulas occurring most frequently in the genitofemoral 
areas and armpits. 
The association between HS and CD has been re-
ported, nevertheless the prevalence of their comor-
bidity is currently unknown (3). The diagnosis of CD 
generally precedes that of HS by the average of 3.5 
years (4-6).
Adalimumab is a fully human monoclonal anti-
body targeted at tumor necrosis factor α (TNF α). It 
is approved for the treatment of moderate to severe 
psoriasis, psoriatic arthritis, rheumatoid arthritis, an-
kylosing spondylitis, juvenile idiopathic arthritis, and 
CD. Recently, several case reports and a placebo-con-
trolled study have indicated that adalimumab might 
also induce resolution in HS (7).
 
CASE REPORT 
 A 50-year-old female nonsmoker with a body mass 
index of 26 was first referred to our department in 
July 1989 with enlarging ulcers on both shins, diag-
nosed to be pyoderma gangrenosum. She reported 
a 6-month history of CD, treated since the onset with 
high-dose corticosteroids and sulfasalazine due to 
severe diarrhoeic episodes. Her family history had no 
bearing on the case. Physical examination revealed 
necrotic ulcerations on both shins with a characteris-
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tic violaceous undermined border. In addition to oral 
prednisone for her CD, cyclosporine and consequent-
ly azathioprine were administered with a complete 
resolution of both ulcers in April 1990.
In 1993, the patient developed inflammatory le-
sions bilaterally in the genitofemoral region with a 
good temporary response to prednisone, azathio-
prine, systemic antibiotics, and various types of topi-
cal antiseptics. 
In December 2010, the disease progressed rapidly 
with development of painful fistulas, some of which 
were spontaneously discharging pus, and abscesses, 
mainly in the left groin (Fig. 1). The patient was clini-
cally diagnosed with HS, Hurley stage II, and an inci-
sion of abscesses was performed. The recurrence of 
inguinal lesions was accompanied by a flare of CD 
with multiple episodes of diarrhea. In addition, the 
continuous long-term regimen of prednisone and 
azathioprine led to a weight gain of 12 kg and elevat-
ed blood levels of triglycerides and cholesterol. 
Clinical exacerbation resulted in depressive disor-
der in the patient, so the immunosuppressive treat-
ment was gradually reduced and the patient was 
included in the adalimumab protocol. In April 2011, 
adalimumab was started at an initial loading dose of 
80 mg, followed by 40 mg every other week, along 
with oral prednisone 15 mg and azathioprine 25 mg 
daily. Over the next month, prednisone and azathio-
prine were tapered and eventually discontinued. 
After five weeks of treatment, the groin lesions had 
almost healed, the pain had improved substantially, 
and remission of CD was achieved. Adalimumab was 
well tolerated with no adverse effects. Eight weeks 
after adalimumab initiation, the fistulas closed com-
pletely, leaving scarring in the genitofemoral area. To 
this date, the patient has not experienced recurrence 
of either CD or HS (Fig. 2) and is back at her pre-treat-
ment weight. 
DISCUSSION
HS is a recurrent inflammatory disease of the 
apocrine glands that can involve the axillae, groin, 
submammary folds, perianal region, and genitalia. It 
is characterized by deep painful nodules, abscesses 
and draining fistulas that heal with scarring. HS usu-
ally develops in young adults and is more frequent in 
women than man. The etiology is unclear at present, 
but smoking, obesity, and familial predisposition are 
considered contributing factors. Current therapy con-
sists of topical or systemic antibiotics, retinoids, and 
immunosuppressive agents, and only has a tempo-
rary or limited effect (4,6). For advanced stages of the 
disease, ablative surgery is essential (8).
Multiple case reports have been published show-
ing promising responses of HS to off-label treatment 
with tumor necrosis factor α inhibitors (6). Recently, 
a placebo-controlled trial with adalimumab showed 
statistically significant improvements of skin lesions 
and pain in HS (7). 
CD may have various dermatological manifesta-
tions, commonly including pyoderma gangrenosum 
(1,2). An increasing number of articles reports the co-
occurrence of CD and HS, and hypothesize the asso-
ciation of the two diseases (3,9). 
Interestingly, our patient developed two signifi-
cant extraintestinal cutaneous complications. Pyo-
derma gangrenosum occurred shortly after the onset 
of CD and healed completely with conservative im-
munosuppressive treatment. Inflammatory lesions 
in the groins, appearing several years later, were at 
first thought to also be pyoderma gangrenosum. 
Figure 1. Genitofemoral region of the patient, with 
draining fistulas and abscesses before treatment.
Figure 2. Genitofemoral area of the patient, with 
closed fistulas and no drainage after 8 weeks of treat-
ment.
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However, further development of fistulas and ab-
scesses with purulent draining was consistent with 
the diagnosis of HS. 
The patient was treated with 40 mg adalimumab 
every other week with successful results, though clin-
ical response rates in HS seem to be higher among 
those who received adalimumab weekly (7). To date, 
adalimumab is the only treatment that has been able 
to control both CD and HS in our patient. Further-
more, it was well tolerated and led to the improve-
ment of her depression and quality of life.
HS is a disabling, difficult-to-manage disease, se-
verely reducing the patient´s quality of life. We sug-
gest that TNF ɑ inhibitors might represent a new 
therapeutic option for patients suffering from severe 
HS and may be useful in the treatment of CD as a co-
morbidity. Further studies are needed to better elu-
cidate the efficacy of these drugs for the treatment 
of HS and to understand the association between CD 
and HS.
CONCLUSION
This case report demonstrates the likelihood of 
association between CD and HS the potential efficacy 
of adalimumab in the treatment and induction of 
long-term remission in both diseases. 
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